MedTrace Logo

Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy

NCT03067831 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-03-17

No results posted yet for this study

Summary

This study is single arm, single center trial to study the safety and efficacy of bone marrow-derived autologous specific populations of stem cells and mesenchymal stem cells for the treatment of Duchenne Muscular Dystrophy (DMD).

Conditions

Interventions

BIOLOGICAL

Stem Cells

Transplantation of purified autologous bone marrow-derived stem cells.

Sponsors & Collaborators

  • Stem Cells Arabia

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-11-30
Completion
2021-12-31

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03067831 on ClinicalTrials.gov